Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before the market opens. In this update, I share what to expect from JNJ's Q2 results and put previous results into perspective. In the main part of the article, I will take a close look at JNJ's earnings adjustments, amid the significant deviation from GAAP earnings (+46% median since 2014).
During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself.
In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024.
Diversified income stocks are a smart choice for investors seeking lifelong cash flow. They offer a reliable stream of income from multiple sources and provide stability and growth potential in any market condition.
Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit growth for the full year. The company is facing risks right now, especially from the litigations due to the talc products, and breaking the support line is also a rather bearish sign. But the stock seems slightly undervalued at this point, and Johnson & Johnson is probably a good investment for investors seeking stability and a bond-like investment.
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
Johnson & Johnson's underlying business has a stable long-term outlook and the stock has a low volatility profile, which makes it an ideal platform for selling put options. The company is trading at a highly attractive valuation, which provides a solid margin of error. Selling put options does sacrifice capital appreciation, but with a nearly 10% annualized yield on offer, this opportunity appears to be a win-win to us.
Dividends can boost your portfolio returns. Johnson & Johnson is a classic example of a value stock with a faithful dividend history.
A federal judge on Friday rejected a bid by a group of cancer victims to block Johnson & Johnson from pursuing a proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products contain cancer-causing asbestos.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson is trying a new approach to resolve thousands of outstanding talc lawsuits. The company's operations are growing in the mid-single digits, and investors can expect more of the same in the years ahead.
Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.